102 related articles for article (PubMed ID: 38739333)
1. Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 May; ():. PubMed ID: 38739333
[No Abstract] [Full Text] [Related]
2. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Elkrief A; Riccuiti B; Alessi JV; Fei T; Kalvin HL; Egger JV; Rizvi H; Thummalapalli R; Lamberti G; Plodkowski A; Hellmann MD; Kris MG; Arcila ME; Baine MK; Rudin CM; Lito P; Ladanyi M; Schoenfeld AJ; Riely GJ; Awad MM; Arbour KC
Oncologist; 2023 Nov; 28(11):978-985. PubMed ID: 37589215
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
[TBL] [Abstract][Full Text] [Related]
6. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
7. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
8. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.
Khawaja H; Briggs R; Latimer CH; Rassel M; Griffin D; Hanson L; Bardelli A; Di Nicolantonio F; McDade SS; Scott CJ; Lambe S; Maurya M; Lindner AU; Prehn JHM; Sousa J; Winnington C; LaBonte MJ; Ross S; Van Schaeybroeck S
Mol Cancer Ther; 2023 Jan; 22(1):135-149. PubMed ID: 36279564
[TBL] [Abstract][Full Text] [Related]
9. Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Oncologist; 2024 Jan; 29(1):e166. PubMed ID: 38000087
[No Abstract] [Full Text] [Related]
10. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I; Roman M; Welch C; Entrialgo-Cadierno R; Salmon M; Santos A; Feliu I; Kovalski J; Lopez I; Rodriguez-Remirez M; Palomino-Echeverria S; Lonfgren SM; Ferrero M; Calabuig S; Ludwig IA; Lara-Astiaso D; Jantus-Lewintre E; Guruceaga E; Narayanan S; Ponz-Sarvise M; Pineda-Lucena A; Lecanda F; Ruggero D; Khatri P; Santamaria E; Fernandez-Irigoyen J; Ferrer I; Paz-Ares L; Drosten M; Barbacid M; Gil-Bazo I; Vicent S
Nat Commun; 2023 Oct; 14(1):6332. PubMed ID: 37816716
[TBL] [Abstract][Full Text] [Related]
11. Adagrasib's Efficacy Sustained in KRASG12C NSCLC.
Cancer Discov; 2023 Nov; 13(11):OF1. PubMed ID: 37702568
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
[TBL] [Abstract][Full Text] [Related]
13. All Roads Lead to Rome: YAP/TAZ Activity Influences Efficacy of KRASG12C Inhibitors.
Johnson CW; Haigis KM
Cancer Res; 2023 Dec; 83(24):4005-4007. PubMed ID: 38098448
[TBL] [Abstract][Full Text] [Related]
14. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Zhang J; Johnson M; Barve M; Bazhenova L; McCarthy M; Schwartz R; Horvath-Walsh E; Velastegui K; Qian C; Spira A
Oncologist; 2023 Apr; 28(4):287-296. PubMed ID: 36892150
[TBL] [Abstract][Full Text] [Related]
15. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH; Gerlach D; Misale S; Petronczki M; Kraut N
Cancer Discov; 2022 Apr; 12(4):924-937. PubMed ID: 35046095
[TBL] [Abstract][Full Text] [Related]
16. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A; Lorthiois E; Barys L; Beyer KS; Bomio-Confaglia C; Burks H; Chen X; Cui X; de Kanter R; Dharmarajan L; Fedele C; Gerspacher M; Guthy DA; Head V; Jaeger A; Núñez EJ; Kearns JD; Leblanc C; Maira SM; Murphy J; Oakman H; Ostermann N; Ottl J; Rigollier P; Roman D; Schnell C; Sedrani R; Shimizu T; Stringer R; Vaupel A; Voshol H; Wessels P; Widmer T; Wilcken R; Xu K; Zecri F; Farago AF; Cotesta S; Brachmann SM
Cancer Discov; 2022 Jun; 12(6):1500-1517. PubMed ID: 35404998
[TBL] [Abstract][Full Text] [Related]
17. Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer.
Heng SZW; Hoo R; Tan DSW
Cancer Discov; 2023 Jul; 13(7):1513-1515. PubMed ID: 37416990
[TBL] [Abstract][Full Text] [Related]
18. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
[TBL] [Abstract][Full Text] [Related]
19. AZD4625 is a Potent and Selective Inhibitor of KRASG12C.
Chakraborty A; Hanson L; Robinson D; Lewis H; Bickerton S; Davies M; Polanski R; Whiteley R; Koers A; Atkinson J; Baker T; Del Barco Barrantes I; Ciotta G; Kettle JG; Magiera L; Martins CP; Peter A; Wigmore E; Underwood Z; Cosulich S; Niedbala M; Ross S
Mol Cancer Ther; 2022 Oct; 21(10):1535-1546. PubMed ID: 35930755
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Ciardiello D; Chiarazzo C; Famiglietti V; Damato A; Pinto C; Zampino MG; Castellano G; Gervaso L; Zaniboni A; Oneda E; Rapisardi S; Bordonaro R; Zichi C; De Vita F; Di Maio M; Parisi A; Giampieri R; Berardi R; Lavacchi D; Antonuzzo L; Tamburini E; Maiorano BA; Parrella P; Latiano TP; Normanno N; De Stefano A; Avallone A; Martini G; Napolitano S; Troiani T; Martinelli E; Ciardiello F; De Vita F; Maiello E
ESMO Open; 2022 Oct; 7(5):100567. PubMed ID: 35994791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
